Nexalin Technology Inc (NXL) Stock Price, Quote & News

Company Profile

Nexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health in the United States and China. The company offers Generation 1, an easy-to-administer medical device which utilizes bioelectronic medical technology to treat anxiety, insomnia, and depression without the need for drugs or psychotherapy; and Generation 2 and Generation 3 headset devices for the treatment of depression, substance use disorder, traumatic brain injur...

Industry: Medical Devices

Sector: Healthcare

Phone: 832 260 0222

Website: www.nexalin.com

Address:

1776 Yorktown, Suite 550, Houston, United States

MrTicker Oct. 30 at 2:49 PM

$NXL solid PR, low volume and small wall seller at $1.60. This will run later

0 · Reply

Dante_s_Inferno Oct. 30 at 2:43 PM

$NXL rsi daily still high 🤞🏻

0 · Reply

TwoToesTrading Oct. 30 at 12:56 PM

$MBRX $MNTS $NXL

0 · Reply

MrTicker Oct. 30 at 12:32 PM

$NXL Nexalin Technology Receives Approval To Sell Its Gen-2 Console Device In Israel BENZINGA 7:31 AM ET 10/30/2025

0 · Reply

MrTicker Oct. 30 at 12:31 PM

$NXL HOUSTON, TX, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc.(NXL) (the “Company” or “Nexalin”), the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced that its Gen-2 Console (“SYNC”), 15 milliamp (mA) neurostimulation device has been granted regulatory approval for sale in Israel by the Israeli Ministry of Health.

0 · Reply

MrTicker Oct. 30 at 12:31 PM

$NXL Nexalin Technology Announces Regulatory Approval to Sell Gen 2 SYNC, 15 mA Neurostimulation DIFS™ Device in Israel GLOBENEWSWIRE 7:30 AM ET 10/30/2025

0 · Reply

isaacwilliams33 Oct. 30 at 12:12 AM

$NXL

0 · Reply

MrTicker Oct. 29 at 8:28 PM

$NXL after hours volume picking up..keep an eye on it

0 · Reply

Kakoon Oct. 29 at 4:52 PM

$NXL

0 · Reply

StockHounding Oct. 25 at 3:24 PM

$EEIQ has been quietly climbing for five straight sessions — and that’s not luck. You can literally see the buyers stepping in near $0.45–$0.46, right where the tape tightened. The filings back it up too: in Form 6-K filed Aug 26 2025 (Item 2 – Operational Update), management confirmed that “the Company continues to strengthen its educational footprint while maintaining financial discipline.” That’s the kind of calm language that pairs nicely with a steady uptrend. $NXL tightening base near support $VCIG showing fresh volume $BNED curling off lows $CRKN low-float magnet forming When the filings sound confident and the chart agrees, that’s not a coincidence — that’s alignment. $EEIQ may be small, but the tape looks like it’s studying for a breakout

0 · Reply

Nexalin Technology Announces Regulatory Approval to Sell Gen 2 SYNC, 15 mA Neurostimulation DIFS™ Device in Israel

Oct 21, 2025, 9:00 AM EDT - 12 days ago

Nexalin's DIFS™ Neurostimulation Shows Cognitive and Brain Network Improvements in Alzheimer's and Dementia Across Three Peer-Reviewed Studies

Oct 13, 2025, 8:30 AM EDT - 20 days ago

Nexalin Technology Expands Scientific Advisory Board with Appointment of Dr. Robert Rothstein to Support Alzheimer's and Traumatic Brain Injury Programs

Oct 10, 2025, 8:00 AM EDT - 23 days ago

Nexalin Technology Announces Attendance at the 2025 Maxim Growth Summit

Oct 8, 2025, 2:45 PM EDT - 25 days ago

Why Is Micro-Cap Stock Nexalin Technology Rallying On Wednesday?

Oct 8, 2025, 8:30 AM EDT - 25 days ago

Nexalin Technology Announces Additional Positive Clinical Results in Alzheimer's Disease with Gen-2 SYNC Neurostimulation Device

Sep 25, 2025, 8:30 AM EDT - 5 weeks ago

Nexalin Technology Announces Issuance of U.S. Patent Covering HALO™ Clarity Device Featuring DIFS™ Technology

Aug 25, 2025, 9:00 AM EDT - 2 months ago

Join Nexalin Technology's Exclusive Live Investor Webinar and Q&A Session on September 9

Aug 1, 2025, 8:30 AM EDT - 3 months ago

Nexalin Technology Appoints Highly Experienced Financial Leader Justin Van Fleet as CFO to Support Nexalin's Next Phase of Growth and Strategic Initiatives

May 28, 2025, 10:00 AM EDT - 5 months ago

Join Nexalin Technology's Exclusive Live Investor Webinar and Q&A Session on June 3

May 13, 2025, 8:30 AM EDT - 6 months ago

Nexalin Technology Reconstitutes Scientific Advisory Board with Leading Experts to Advance Alzheimer's Program Amid Encouraging Data

May 6, 2025, 2:40 PM EDT - 6 months ago

Nexalin Technology Announces Closing of Previously Announced $5.0 Million Underwritten Public Offering

May 5, 2025, 8:20 AM EDT - 6 months ago

Nexalin Technology Announces Pricing of $5.0 Million Public Offering of Common Stock

May 1, 2025, 10:30 AM EDT - 6 months ago

Nexalin Technology Initiates FDA Q-Submission Process for Gen-2 SYNC Following Encouraging Data and Preliminary FDA Feedback

Apr 24, 2025, 9:00 AM EDT - 6 months ago

Nexalin Technology Receives IRB Approval in Brazil and Begins Clinical Trial for Anxiety and Insomnia

Apr 23, 2025, 9:15 AM EDT - 6 months ago

Nexalin Technology Announces Completion of Phases One Through Five of its Virtual Clinic and Digital Ecosystem for HALO™ Clinical Research and Patient Management

Apr 21, 2025, 8:00 AM EDT - 6 months ago

Nexalin Technology Expresses Strong Support for Health Tech Investment Act to Advance Medicare Reimbursement for AI-Enabled Devices

Apr 14, 2025, 12:30 PM EDT - 7 months ago

Nexalin Technology Secures USPTO Patent for Deep Intracranial Frequency Stimulation (DIFS™) Technology in Treating Substance Use Disorders

Apr 2, 2025, 8:30 AM EDT - 7 months ago

Nexalin Technology Enrolls First Patients and Advances Toward Treatment in UCSD Clinical Trial

Mar 26, 2025, 8:30 AM EDT - 7 months ago

Join Nexalin Technology's Exclusive Live Investor Webinar and Q&A Session on April 3

Mar 3, 2025, 8:30 AM EST - 8 months ago

Nexalin Technology Receives Notice of Allowance from the USPTO for Patent Covering Deep Intracranial Frequency Stimulation (DIFS™) Technology for Opioid and Other Substance Use Disorders

Feb 28, 2025, 8:30 AM EST - 8 months ago

Nexalin Technology Announces Initiation of Patient Recruitment for UCSD's TBI & PTSD Clinical Study Following IRB Approval

Feb 26, 2025, 8:30 AM EST - 8 months ago

Nexalin Technology Welcomes General Wesley Clark to Military & Government Advisory Board

Feb 18, 2025, 8:30 AM EST - 9 months ago

Nexalin Technology Announces UCSD IRB Approval for use of HALO™ Clarity in Clinical Trials for mTBI and PTSD Treatment

Feb 10, 2025, 9:00 AM EST - 9 months ago

Nexalin Appointed as Industry Co-Chair of National TBI Registry Coalition

Feb 3, 2025, 8:30 AM EST - 9 months ago

Nexalin's Breakthrough DIFS™ Neurostimulation Device Demonstrates Reduction in Blood Pressure while Enhancing Mental Health According to New Landmark Study

Jan 23, 2025, 11:00 AM EST - 10 months ago

Join Nexalin Technology's Exclusive Live Investor Webinar and Q&A Session, Today, January 23

Dec 23, 2024, 10:00 AM EST - 11 months ago

Nexalin Technology Completes Phase 1of its Innovative Virtual Clinic

Nov 26, 2024, 10:00 AM EST - 1 year ago

New Peer-Reviewed Publication Validates Nexalin's Deep Intracranial Frequency Stimulation (DIFS) Technology, Reinforcing Leadership in High-Growth Neuromodulation Market

Nov 1, 2024, 2:00 PM EDT - 1 year ago

Join Nexalin Technology's Exclusive Live Investor Webinar and Q&A Session on November 5th

Nov 1, 2024, 10:34 AM EDT - 1 year ago

Nexalin Technology Regains Compliance with Nasdaq Continued Listing Requirements

Nov 1, 2024, 9:00 AM EDT - 1 year ago

LOBO EV and Nexalin Technology Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

LOBO

Oct 28, 2024, 8:30 AM EDT - 1 year ago

Nexalin Technology Announces Landmark Study on Alzheimer's Disease and Deep Intracranial Frequency Stimulation Published in Journal of Alzheimer's Disease

Oct 25, 2024, 9:00 AM EDT - 1 year ago

Nexalin Technology and Calidi Biotherapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

CLDI

Oct 22, 2024, 2:15 PM EDT - 1 year ago

Nexalin Technology Announces Planned Clinical Trial Utilizing Gen-3 Halo Headset in Partnership with UC San Diego & San Diego VA

Oct 17, 2024, 8:30 AM EDT - 1 year ago

New Study Shows Nexalin's Deep Intracranial Frequency Stimulation (DIFS) Significantly Improves Memory and Cognitive Function in Alzheimer's Patients

Oct 14, 2024, 8:30 AM EDT - 1 year ago

Nexalin Technology Appoints Carolyn Shelton as Senior Vice President of Clinical, Quality & Regulatory Affairs

Sep 5, 2024, 9:00 AM EDT - 1 year ago

Nexalin Technology Participates in Congressional Roundtable Focused on Emerging Virtual Therapeutic Options for Opioid Treatment

Jul 26, 2024, 9:55 AM EDT - 1 year ago

Nexalin Interview to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

LOBO

Jul 18, 2024, 8:30 AM EDT - 1 year ago

Nexalin Technology Selected to Join Industry Coalition: Breaking Barriers to Substance Use Recovery

Jul 1, 2024, 2:45 PM EDT - 1 year ago

Nexalin Technology Announces Closing of $5.2 Million Public Offering

Jun 27, 2024, 9:15 PM EDT - 1 year ago

Nexalin Technology Announces Pricing of $5.2 Million Public Offering

Jun 20, 2024, 8:30 AM EDT - 1 year ago

Nexalin Technology Awarded Key Patent Related to its Non-Invasive, Frequency-Based Deep-Brain Stimulation Device for the Treatment of Alzheimer's and Dementia

Jun 14, 2024, 9:00 AM EDT - 1 year ago

Nexalin Technology and VolitionRX Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

VNRX

Jun 13, 2024, 3:00 PM EDT - 1 year ago

Nexalin Technology Announces Regulatory Approval to Sell Nexalin's Gen-2, 15 mA Neurostimulation Device by the Brazilian Health Regulatory Agency (Anvisa)

Jun 4, 2024, 8:30 AM EDT - 1 year ago

Nexalin Technology to Present at the Spring MicroCap Rodeo Conference on June 6th

Jun 3, 2024, 8:30 AM EDT - 1 year ago

FDA Provides Feedback and Reaches Consensus on Nexalin's Design for Planned Anxiety and Insomnia Clinical Studies of its Gen-3 HALO Clarity™ Headset Device

May 22, 2024, 8:30 AM EDT - 1 year ago

Nexalin America Selected to Join the National Traumatic Brain Injury Registry Coalition to Propel TBI Awareness and Research Efforts

Apr 10, 2024, 8:30 AM EDT - 1 year ago

Nexalin Technology CEO Provides Letter to Shareholders

Apr 4, 2024, 1:00 PM EDT - 1 year ago

Nexalin Technology Awarded Key Patent Related to its Gen-3 HALO Clarity™, a Non-Invasive, Frequency-Based Deep-Brain Stimulation Device

MrTicker Oct. 30 at 2:49 PM

$NXL solid PR, low volume and small wall seller at $1.60. This will run later

0 · Reply

Dante_s_Inferno Oct. 30 at 2:43 PM

$NXL rsi daily still high 🤞🏻

0 · Reply

TwoToesTrading Oct. 30 at 12:56 PM

$MBRX $MNTS $NXL

0 · Reply

MrTicker Oct. 30 at 12:32 PM

$NXL Nexalin Technology Receives Approval To Sell Its Gen-2 Console Device In Israel BENZINGA 7:31 AM ET 10/30/2025

0 · Reply

MrTicker Oct. 30 at 12:31 PM

0 · Reply

MrTicker Oct. 30 at 12:31 PM

$NXL Nexalin Technology Announces Regulatory Approval to Sell Gen 2 SYNC, 15 mA Neurostimulation DIFS™ Device in Israel GLOBENEWSWIRE 7:30 AM ET 10/30/2025

0 · Reply

isaacwilliams33 Oct. 30 at 12:12 AM

$NXL

0 · Reply

MrTicker Oct. 29 at 8:28 PM

$NXL after hours volume picking up..keep an eye on it

0 · Reply

Kakoon Oct. 29 at 4:52 PM

$NXL

0 · Reply

StockHounding Oct. 25 at 3:24 PM

0 · Reply

BioTuesdays Oct. 23 at 1:53 PM

$NXL has announced that three independently published, peer-reviewed clinical studies collectively demonstrate the ability of its proprietary 15 mA Gen-2 Nexalin DIFS technology to improve cognition, restore brain activity, and enhance neuron connectivity in patients with Alzheimer’s disease (AD) https://biotuesdays.com/2025/10/21/three-peer-reviewed-studies-reveal-nexalins-difs-potential-in-ad/

0 · Reply

XaviersLessons Oct. 23 at 6:09 AM

How much volume do you think it takes to Gap BBGI up? BBGI has not even 700k shares float and recent news. Hoping for a 100% run on BBGI $VFS $NXL $CHPT $ANY Watchlist \\

0 · Reply

Dante_s_Inferno Oct. 22 at 10:41 AM

$NXL wtf

0 · Reply

Berakhot Oct. 21 at 9:26 PM

$NXL

0 · Reply

Berakhot Oct. 21 at 9:08 PM

$NXL

0 · Reply

indybucfan Oct. 21 at 1:25 PM

$NXL

0 · Reply

MrTicker Oct. 21 at 1:11 PM

$NXL normal market hours in 20 minutes. Should see nice volume increase and looking for that $2+ break on solid news.

0 · Reply

RPGinbound Oct. 21 at 1:11 PM

$NXL People have been waiting for this news

0 · Reply

MrTicker Oct. 21 at 1:02 PM

$NXL Nexalin’s DIFS™ Neurostimulation Shows Cognitive and Brain Network Improvements in Alzheimer’s and Dementia Across Three Peer-Reviewed StudiesThree Independent Studies Published in “Alzheimer’s Research & Therapy,” “Journal of Alzheimer’s Disease,” and “Radiology” Validate Nexalin’s Non-Invasive Approach with Consistent Cognitive and Neuroimaging Benefits GLOBENEWSWIRE 8:00 AM ET 10/21/2025

0 · Reply

DaBullRunner Oct. 21 at 1:01 PM

$NXL there it goes…. ANVS will be one of my biggest swings of the year 🏆✅ Watch and learn

0 · Reply

SadyK189 Oct. 21 at 3:23 AM

$NXL Looking good on daily chart. Key support at 1.2 - 1.34. Next key level to test 2.15 - 2.35. It may take sometime though. Currently at 1.64

0 · Reply

SPYmyQQQ Oct. 20 at 10:08 PM

🎯 Target Hit 🏁 📨 From Oct 13, 2025 💊 $NXL 💵 Entry: $1.3700 ✅ Exit: $1.5900 💰 P/L: +16.06% 👉 FREE TRIAL! spymyqqq/join/

0 · Reply

Market Cap	26.47M
Revenue (ttm)	170,000.00
Net Income (ttm)	-7.61M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-4,476.47%
Debt to Equity Ratio	0.00

Volume	301,900
Avg Vol	5,497,118
Day's Range	N/A - N/A
Shares Out	17.65M
Stochastic %K	41%
Beta	3.59
Analysts	Strong Sell
Price Target	$4.00